Text and Data Mining valid from 2020-02-21
Received: 29 July 2019
Accepted: 7 February 2020
First Online: 21 February 2020
Ethics approval and consent to participate
: Written informed consent was obtained for this ethics board-approved investigation (Local IRB number: AZ_189_15B). (Ethics committee of the Friedrich-Alexander University Erlangen-Nürnberg).
: Not applicable.
: Dr. Guermazi has received consultancies, speaking fees, and/or honoraria from Sanofi-Aventis, Merck Serono, and TissuGene and is President and shareholder of Boston Imaging Core Lab (BICL), LLC a company providing image assessment services. Dr. Roemer is Chief Medical Officer and shareholder of BICL, LLC. None of the other authors have declared any competing interests.